Cellular Immune Responses to Fractional and Standard COVID-19 Booster Doses Over 12 Months

A randomized controlled trial of 601 Mongolian adults compared long-term immune responses to standard and fractional booster doses of the BNT162b2 vaccine. The study measured binding antibodies, neutralizing antibodies, and T-cell responses against wild-type and JN.1 SARS-CoV-2 variants over 12 months. Fractional dosing produced comparable and robust long-term humoral and cellular immune responses to a standard dose.

Use Cases

• Compare long-term T-cell durability between vaccine dose regimens based on activation-induced marker (AIM) and intracellular cytokine staining (ICS) data.
• Analyze antibody persistence against emerging variants based on anti-Spike IgG and neutralizing antibody measurements over time.
• Evaluate the equivalence of fractional and standard booster dosing strategies based on immune response metrics across different priming vaccines.

Strengths

• Includes data from a randomized controlled trial with 601 participants, providing a structured comparison.
• Tracks immune responses over a 12-month period, allowing for analysis of durability.
• Measures multiple immune parameters, including antibodies and T-cell responses against two viral variants.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the single-country (Mongolia) study population.

Provenance

Source

Nadia Mazarakis via figshare

Collection Method

Data collected from a randomized controlled trial.

Time Range

Follow-up period of 12 months post-vaccination.

Freshness

Last updated 2026-04-22 05:49:49; freshness should be verified.

Geography

Mongolia